Pulmonx Corporation is a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema.
Pulmonx develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD.
Pulmonx was founded in 1995 by Rodney Perkins. The company is headquartered Redwood City, California, and Neuchâtel, Switzerland.
The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches.
Pulmonx is backed by Ally Bridge Group, Adage Capital Management, HealthQuest Capital, Partner Fund Management, Rock Springs Capital and others. The company raised $66M in a new round of funding on May 05, 2020. This brings Pulmonx's total funding to $276.9M to date.